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The results shown in Fig. 1 suggest that the human neuroblastoma line contains monoamine oxidase activity of an A type, whereas that of MC63 cells is predominantly type B. At a concentration of 10m-clorgyline, monoamine oxidase from IMR32 cells was almost completely inhibited, whereas that from MC63 cells was only slightly so.
To clarify further the possible differences between monoamine oxidase in the two cell lines, 0.5 % (w/v) Triton X-100 extracts of the two cell lines were made to react with antiserum raised against purified human placental monoamine oxidase. The purification of this placental enzyme is briefly described in Scheme 1. This antiserum reacted with crude human placental mitochondrial extracts in 0.5 % (w/v) Triton X-100 to form a single precipitin line in double-diffusion tests, but failed to react with 0.5 % (w/v) Triton X-100 extracts of human platelets, or partially purified human platelet monoamine oxidase. These preparations should contain only type B enzyme (see Donnelly et al., 1976) . The antiserum also reacted with crude extracts of IMR32-cell mitochondria but not those prepared from MC63 cells, even when the latter extract was in fourfold excess with respect to monoamine oxidase activity. Further work is required to clarify the nature of the antigen recognized by this antiserum. However, it is apparent that the neuroblastoma line expresses a form of monoamine oxidase with properties similar to those described for type A enzyme and can be distinguished from the form expressed in the HeLa-cellline derivative MC63. Quinuclidinyl benzilate is a potent, specific muscarinic antagonist (Albanus, 1970; Meyerhoffer, 1972) and the 3H-labelled compound has been used in the study of the muscarinic receptors in the brains of rat and monkey (Yamamura & Snyder, 1974; Yamamura et al., 1974a,b) . Yamamura & Snyder (1974) found that whencrude subcellular fractions of rat brain were incubated with [3H]quinuclidinyl benzilate, 57 % of the specific binding was found in the crude mitochondria1 fraction (PJ and 35% in the microsomal fraction (P3). The specific binding of [3H] quinuclidinyl benzilate in the regions of rat brain was greatest in the striatum. In both the regional and the subcellular studies, the high specific binding of [3H]quinuclidinyl benzilate appeared to parallel choline acetyltransferase (EC 2.3.1.6) activity. The caudate nucleus, part of the striatum, is rich in cholinergic activity and is reported to have a high concentration of muscarinic receptors (Hiley & Burgen, 1974) . In the present study [3H]quinuclidinyl benzilate was used as a marker for muscarinic receptors in subcellular fractions of the bovine caudate nucleus, b e f~r e these enriched fractions were used for studies of choline metabolism. 566th MEETING, CAMBRIDGE Bovine brains were obtained from the slaughterhouse and the caudate nuclei were removed within 1 h of death. These were homogenized in icecold 0.25~-sucrose and subcellular fractions prepared by a slight modification of the method of Gray & Whittaker (1962) . In preliminary experiments the crude mitochondria1 fraction was used for binding studies and was diluted to give a concentration of 6mg of proteinlml. To 2nd of sodium/potassium phosphate buffer (0.05 M), pH 7.4, containing 2 n~-[~H]quinuclidinyl benzilate was added 0.1 ml of the P2 fraction. The tubes were left in a water bath at 37°C
for Smin and the fraction was then collected by rapid tiltration of the incubation mixture on to a glass-fibre disc (Whatman GF/B). The unbound [3H]quinuclidinyl benzilate was washed away with 2 x 5 ml of ice-cold buffer. The disc was dropped into a counting vial, l O m l of scintillator was added, and the vial left for 16h in a warm place before counting for radioactivity. The radioactivity was a measure of the total quinuclidinyl benzilate bound to the Pz fraction. To determine the specifically bound quinuclidinyl benzilate, a solution of atropine in buffer was added to the incubation mixture after the 5 min preliminary period with [3H]quinuclidinyl benzilate, and the incubation continued for a further 90min. The sample was filtered, washed and counted for radioactivity as described above. The radioactivity remaining on the disc constituted the nonspecifically bound quinuclidinyl benzilate. From the values for the total and nonspecifically bound quinuclidinyl benzilate, the amount of specifically bound quinuclidinyl benzilate could be calculated. A final concentration of 27matropine was found to give optimum removal of specifically bound [3H]quinuclidinyl benzilate, i.e. 0.20f0.06 (n = S)pmol/mg of protein, which was40% of the total amount bound.
Nicotine and a nicotine antagonist tubocurarine failed to displace specifically bound [3H]quinuclidinyl benzilate at concentrations as high as 2 5~~. An interesting effect was found with gallamine, generally considered to be a nicotinic antagonist, which at a concentration of 3 p~ removed 50 % of the specifically bound [3H]quinuclidinyl benzilate. This is presumably because of its muscarinic side effects (Rathbun & Hamilton, 1970; Goat & Feldman, 1971) .
When the conditions for measuring specific binding in the Pz fraction of the bovine caudate nucleus had been established, the method was applied to further subfractions. In the early preparations it was found that the recovery of protein and synaptosomal marker enzymes in the classical P2B fraction was very low. Investigation of the P1 fraction seemed to indicate that a very incomplete cell disruption was taking place. Experiments were therefore carried out in which the P1 fraction was rehomogenized three times and a series of Si fractions prepared. From these, the PzB fractions were isolated and analysed 
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activity/mg of protein in the fraction activity/mg of protein in the total homogenate, for protein and marker enzymes and for quinuclidinyl benzilate binding. It became obvious that at least three homogenizations (0.1 1-0.15mm clearance) were necessary to give the maximum yield of synaptosomes from the caudate nucleus. The relative specific activity of choline acetyltransferase was high in all four preparations and succinate dehydrogenase demonstrated the presence of intraterminal mitochondria. However, a pattern of specific binding was beginning to emerge, and it was only in the synaptosomes from the first two homogenizations that the relative specific activity of the synaptosomal binding, when compared with that of the homogenate, was greater than 1 (Table 1) .
Possibly a crude but enriched fraction of 'muscarinic synaptosomes' may be prepared in this way.
The other interesting finding was the high specific binding of quinuclidinyl benzilate to the microsomal fraction [0.36fO.O9(5)pmol/mg of protein] and to the myelin [0.44f0.15(5)]. The myelin was purified by repeated exposure to hypo-osmotic shock and centrifugation until the acetylcholinesterase value was negligible, but the quinuclidinyl benzilate binding persisted. Other workers have found a high specific binding to the microsomal fraction. Yamamura & Snyder (1974) demonstrated that [3H]quinuclidinyl benzilate was specifically bound by the microsomal fraction and Salvaterra et al.
(1 975) demonstrated a considerable binding of the nicotinic antagonist a-bungarotoxin to the microsomal fraction. The reason for this specific binding in the microsomal fraction remains unclear. Salvaterra et al. (1975) suggest that the microsomal fraction may contain nicotine-sensitive dendritic elements. Csillik (1975) has suggested that in Renshaw cells, dendritic areas may have muscarinic and other receptors, and these regions would be present in the microsomal fraction.
